Bio-outsourcing

EpimAb and Kymab join forces to develop bispecific Abs

11-Oct-2016 By Dan Stanton

EpimAb Biotherapeutics will combine its bispecific antibody generating technology with Kymab’s mouse mAb production platform in a cross-licensing deal between the two firms.

Teva bolsters its biosimilar business through $160m deal with Celltrion

11-Oct-2016 By Dan Stanton

Teva has partnered with Celltrion to commercialise versions of Roche’s Herceptin and Rituxan, helping fill a gap in its second wave biosimilars pipeline.

Merck opens testing plant in latest Korean bioprocessing investment

07-Oct-2016 By Dan Stanton

Germany’s Merck has opened a bioprocessing collaboration centre in Songdo, Incheon - the latest investment supporting the burgeoning Korean biopharma industry.

Industry recognises continuous downstream tech at CPhI and Biotech Week

07-Oct-2016 By Dan Stanton

The conservatism of the biotech industry held back adoption of continuous manufacturing tech but this is now changing says Novasep, winner of the CPhI bioprocessing award.

Lonza constructing dedicated suite to make Clovis breakthrough mAb

06-Oct-2016 By Dan Stanton

Lonza will construct a dedicated suite to produce commercial supply of rucaparib API on behalf of Clovis Oncology.

Dispatches from CPhI Worldwide

Single-use tech will impact the 'extremely consolidated' bio-CMO space, expert

06-Oct-2016 By Dan Stanton

Lonza and Boehringer-Ingelheim dominate the consolidated biologics CMO space but disposable technologies and improved yields are beginning to change this, says PharmSource’s Jim Miller.

BPI Boston

Continuous bioprocessing next logical step after single-use adoption, Pall

06-Oct-2016 By Dan Stanton

The strong adoption of single-use technology is enabling industry to transition towards continuous bioprocessing systems, says Pall Corporation.

CDMO MabPlex expands cGMP manufacturing facilities in China

05-Oct-2016 By Melissa Fassbender

MabPlex International is expanding its biomanufacturing facilities in China to meet biologic demand for “the foreseeable future.”

Sartorius Stedim Biotech adds PESU membranes to benchtop filtration techs

04-Oct-2016 By Staff reporter

Sartorius Stedim Biotech (SSB) claims benchtop vaccine and protein purification techs could save developers €2000 per batch and reduce processing time by 60%.

Lonza expands cell and gene therapy plant it is building in Texas

30-Sep-2016 By Gareth Macdonald

The cell and gene therapy plant Lonza is building in Pearland, Texas will be bigger than originally planned to according to the city’s economic development corporation.

GE opens Korean tech training centre to support blossoming biopharma industry

30-Sep-2016 By Dan Stanton

GE Healthcare has opened a $7.4m bioprocessing technology and training centre on the back of South Korea’s commitment to the biosimilar and biomanufacturing industries.

UPDATE

Regeneron thanks Abec for helping it avoid "gremlins" during bio plant set-up

27-Sep-2016 By Gareth Macdonald

Abec has completed work on Regeneron’s biologics facility in Ireland just 28 months after it was hired to kit out the repurposed computer plant.

Momenta taps BioFactura's NS0 cell line tech for biosimilar candidate

21-Sep-2016 By Dan Stanton

Momenta Pharmaceuticals has partnered on the development of an undisclosed biosimilar using BioFactura’s StableFast biomanufacturing platform.

Adaptimmune selects cell therapy third-party PCT to make SPEAR T-Cells

20-Sep-2016 By Dan Stanton

Adaptimmune Therapeutics has entered a five-year manufacturing deal with PCT for its SPEAR T-cell pipeline ahead of the opening of its own facility in Philadelphia.

Looking for a single-use modular biologics plant in Ireland? Talk to GE

20-Sep-2016 By Dan Stanton

GE Healthcare is in discussions with companies looking to buy four fully-equipped ‘off-the-shelf’ facilities as part of a €150m investment into a biomanufacturing campus in Ireland.

UK and Ireland biomanufacturing centres ink cell line deal with Horizon

20-Sep-2016 By Dan Stanton

Horizon Discovery says flexibility and openness helped the UK’s Centre for Process Innovation (CPI) and Ireland’s NIBRT choose to provide its GS null CHO cell line to the biologics industry.

Rentschler doubles capacity with new manufacturing plant

16-Sep-2016 By Gareth Macdonald

Rentschler Biotechnologie has opened a facility at its site in Laupheim, Germany and plans to create 200 new jobs.

Promising Korea? CMO giant Samsung Biologics opens doors to Biopharma-Reporter

16-Sep-2016 By Dan Stanton

Since 2011, Samsung Biologics has built two plants, gained Bristol-Myers Squibb and Roche as clients and launched an IPO. With a third facility under construction, Biopharma-Reporter visited to see the CMO’s ambition in action.

Fragile X drug developer Fulcrum to use Horizon's CRISPR to find gene targets

15-Sep-2016 By Gareth Macdonald

Fulcrum Therapeutics will use a CRISPR gene editing-based platform to identify genetic targets under a deal with Horizon Discovery Group.

Lonza licenses rights to sell synthetic AAVs to gene therapy developers

14-Sep-2016 By Gareth Macdonald

Lonza has licensed rights to synthetic adeno-associated viral (AAV) vectors developed by scientists at US hearing research centre, Massachusetts Eye and Ear.

Customisable chromatography resin maker Avitide boosted by Series D funding

14-Sep-2016 By Dan Stanton

Custom-made affinity resins can offer biomanufacturers flexibility and shorten development timelines says Avitide, fresh from securing Series D financing from Mithril Capital Management.

Selexis to triple cell line capacity on back of increased demand

13-Sep-2016 By Dan Stanton

Mammalian cell line developer Selexis has signed a fourth licensing agreement in as many months and is planning a "major expansion" early next year ahead of anticipated demand.

AGC leaps into microbial CMO space through Biomeva acquisition

13-Sep-2016 By Dan Stanton

Japanese glass solution provider AGC Asahi Glass has bought Germany’s Biomeva in a bid to launch itself into the international microbial CMO space.

Avid to construct third plant with two 1,000L single-use bioreactors

13-Sep-2016 By Dan Stanton

Avid Bioservices will construct a clinical manufacturing plant later this year just months after production began at a second facility.

Merck aiming to help biopharmas make CHO cells resistant to MVM

09-Sep-2016 By Gareth Macdonald

Germany's Merck says gene editing can make CHO cells resistant to a tiny mouse virus that continues to be a problem for even animal component-free production processes.

INFOGRAPHIC

The future of the biopharma industry: emerging markets and biosimilars

07-Sep-2016 By Dan Stanton

China and India are the most important growth markets for biopharmaceutical manufacturers, according to our state of the industry survey.

SGS opens dedicated extractables and leachables testing facility

06-Sep-2016 By Melissa Fassbender

SGS has opened a new Wiesbaden-based facility to serve as its global Center of Excellence for Extractable Studies and Impurities Profiling as customer demand increases.

Catalent Q4 results

Catalent to add two 2,000L bioreactors in $34m WI biologics plant expansion

30-Aug-2016 By Dan Stanton

Catalent has more than doubled its biologics business since it went public in 2014, but the sector still represents less than 5% of the CDMO’s revenues.

EMA says biologics developers need to be extra vigilant

19-Aug-2016 By Gareth Macdonald

Biologics developers need to be more vigilant about immunogenicity and manufacturing changes than small molecule drug manufacturers according to the EMA.

Public Patheon's $2bn warchest may bolster biologics offering, analyst

17-Aug-2016 By Dan Stanton

Biomanufacturing demand will drive revenues for Patheon according to an Evercore ISI analyst, who has predicted the newly-listed CDMO will strengthen its capabilities through M&A.

Cognate to make dendritic cell cancer vaccine in $2.2m deal with Asterias

17-Aug-2016 By Dan Stanton

Asterias Biotherapeutics has selected Cognate BioServices for the process development and manufacture of its autologous dendritic cell vaccine candidate, AST-VAC1.

Cell preservation reliability: Bellicum inks 10-year deal with Biolife

10-Aug-2016 By Dan Stanton

Cell therapy firm Bellicum Pharmaceuticals has entered a ten-year agreement for the supply of BioLife Solutions’ cryopreservation media.

Single-use vendors will continue benefiting from Biopharma demand, expert

10-Aug-2016 By Dan Stanton

Vendors have again reported high growth in sales of single-use systems and according to Eric Langer from BioPlan Associates this trend is set to continue.

Merck confirms plan to close sites in US, Brazil and Japan

Merck trims network to realise Sigma-Aldrich production synergies

09-Aug-2016 By Dan Stanton

Germany’s Merck has earmarked four facilities for closure and says it is evaluating others, following its acquisition last year of Sigma-Aldrich.

Repligen up on Protein A and bioprocessing tech as US approves more mAbs

05-Aug-2016 By Dan Stanton

High US approval rates of monoclonal antibodies is driving demand for Protein A, and with the arrival of biosimilars this is unlikely to slow down, says Repligen.

Biologics and biosimilar services drive Q2 sales boost for CRL

04-Aug-2016 By Dan Stanton

Charles River says it is capitalising on the growing number of biologics in development, with its manufacturing business seeing double-digit growth led by demand for biosafety and cell banking services.

Biopharma reliant on 'try before you buy' model say CAPEX heavy vendors

02-Aug-2016 By Dan Stanton

Investing in facilities that allow customers to test biomanufacturing equipment and processes is both cost-effective and necessary due to Biopharma's regulatory demands, say Merck, Pall and GE.

Thermo Fisher: ‘Biopharma’s drive for efficiency plays into our sweet spot’

29-Jul-2016 By Dan Stanton

Increased biologics both on the market and in development and demand for greater manufacturing efficiencies have led to another strong quarter for Thermo Fisher.

Single-use driving double digit growth for Pall and Sartorius

26-Jul-2016 By Dan Stanton

Bioprocess equipment vendors Pall and Sartorius have each cited demand for single-use technologies as a growth driver in the first half 2016.

Axol to supply Metrion with stem cells under cardiac safety testing accord

26-Jul-2016 By Gareth Macdonald

Axol Biosceince has teamed up with Metrion Biosciences to provide drug developers with a more accurate means of testing drugs' cardiac safety using stem cells.

J&J feeling biosimilar impact but no plans to outsource Remicade production

26-Jul-2016 By Dan Stanton

Janssen will keep production of its monoclonal antibody Remicade (infliximab) in-house despite encroaching biosimilar competition in the US.

Teewinot gets US patent for bioreactor used to make synthetic cannabinoid APIs

22-Jul-2016 By Gareth Macdonald

Teewinot Life Sciences has been granted a US patent for a bioreactor it uses to produce synthetic cannabinoids.

Lonza: Biologic APIs boosted H1 revs and CAR-T deal will help sustain growth in H2

20-Jul-2016 By Gareth Macdonald

Lonza has increased its 2016 earnings guidance after strong H1 growth of its biologic APIs business.

MilliporeSigma investing $115m in new North American hub

19-Jul-2016 By Melissa Fassbender

The 280,000-square-foot facility will be built in Burlington, Massachusetts and will include a customer collaboration laboratory and training center, in addition to office space.

Pluristem poised for US cell therapy trial after contracting CRO

12-Jul-2016 By Gareth Macdonald

Pluristem has said it will begin a US trial of a cell therapy for people lacking bone marrow this year after hiring a CRO.

Two component ‘bio-ink’ could help advance 3D printing of tissues

06-Jul-2016 By Phil Taylor

Researchers in the UK say they have developed a ‘bio-ink’, which overcomes obstacles holding back the use of 3D printing to make complex tissues.

UK's commercial DNA foundry a step on path to 'bioeconomy'

05-Jul-2016 By Phil Taylor

The opening of the UK's first synthetic biology foundry promises to usher in a new era of cheaper and more accessible DNA synthesis.

Corning adds Biological Industries' xeno-free stem cell medium to portfolio

29-Jun-2016 By Dan Stanton

Corning has struck a deal to commercialise NutriStem hPSC Medium, a xeno-free stem cell culture supplement manufactured by Biological Industries.

Sartorius $90m IntelliCyt acquisition adds cell analysis capabilities

29-Jun-2016 By Dan Stanton

Sartorius has expanded its bio-analytics capabilities through the $90m (€81m) acquisition of IntelliCyt.

Update

Pfizer and GE team on $350m modular biosimilars plant in China

28-Jun-2016 By Dan Stanton

Pfizer has struck a strategic partnership with GE Healthcare to construct and equip a biomanufacturing centre focused on producing biosimilars for China.